The 2026 Consensus Statement on the Algorithm for Management of Adults with Type 2 Diabetes: Atherosclerotic Cardiovascular Disease Management (Episode 7)

The 2026 Consensus Statement on the Algorithm for Management of Adults with Type 2 Diabetes: Stroke and Transient Ischemic Attack (Episode 8)

In this episode, we review the 2026 Consensus Statement algorithm for stroke and transient ischemic attack management in adults with type 2 diabetes. Topics include stroke risk in type 2 diabetes, evidence supporting GLP-1 receptor agonists for stroke risk reduction, and cardiovascular outcomes with dulaglutide, liraglutide, injectable semaglutide, tirzepatide, and pioglitazone. We also discuss secondary stroke prevention in adults with insulin resistance, prediabetes, or type 2 diabetes, lower dose pioglitazone to improve tolerability, the limited role of SGLT2 inhibitors in stroke prevention, and practical evidence based strategies for reducing stroke risk in clinical practice.

The 2026 Consensus Statement on the Algorithm for Management of Adults with Type 2 Diabetes: Atherosclerotic Cardiovascular Disease Management (Episode 7)

In this episode, we review the 2026 Consensus Statement ASCVD management algorithm for adults with Type 2 Diabetes. Topics include cardiovascular risk reduction, major adverse cardiovascular events, and the evidence supporting GLP-1 receptor agonists and SGLT2 inhibitors for cardiovascular protection. We discuss semaglutide, liraglutide, dulaglutide, tirzepatide, and the cardiovascular safety of DPP-4 inhibitors. We also review treatment recommendations for adults with established ASCVD or high cardiovascular risk, the role of SGLT2 inhibitors in heart failure and chronic kidney disease, and practical evidence based strategies for cardiovascular risk reduction in clinical practice.

The 2026 Consensus Statement on the Algorithm for Management of Adults with Type 2 Diabetes: Chronic Kidney Disease Management (Episode 6)

In this episode, we review the 2026 Consensus Statement algorithm for the management of chronic kidney disease in adults with Type 2 Diabetes. Topics include SGLT2 inhibitors as foundational renoprotective therapy, evidence based pharmacologic management of diabetic kidney disease, and strategies to reduce CKD progression, kidney failure, and cardiovascular events. We discuss canagliflozin, dapagliflozin, empagliflozin, finerenone, and GLP-1 receptor agonists, including semaglutide and the FLOW trial, along with eGFR initiation thresholds, albuminuria guided treatment, and combination therapy for persistent residual kidney risk. We also review therapeutic sequencing, cardiorenal protection, monitoring of eGFR, albuminuria, and serum potassium, board relevant treatment recommendations, pivotal clinical trials, and high yield facts for ABIM certification, recertification, LKA, and clinical practice.

The 2026 Consensus Statement on the Algorithm for Management of Adults with Type 2 Diabetes: Heart Failure Management (Episode 5)

In this episode, we review the 2026 Consensus Statement algorithm for heart failure management in adults with Type 2 Diabetes. Topics include the foundational role of SGLT2 inhibitors, heart failure with reduced and preserved ejection fraction, and evidence based pharmacologic therapy. We discuss dapagliflozin, empagliflozin, sotagliflozin, GLP-1 receptor agonists, and the role of semaglutide, tirzepatide, and liraglutide in different heart failure phenotypes. We also review medications that may worsen heart failure, including thiazolidinediones and selected DPP-4 inhibitors, therapeutic priorities for reducing hospitalization and cardiovascular mortality, and board relevant treatment recommendations, key clinical trials, and high yield facts to remember for exam preparation and clinical practice.

The 2026 Consensus Statement on the Algorithm for Management of Adults with Type 2 Diabetes: Hypertension Management (Episode 4)

In this episode, we review the 2026 Consensus Statement hypertension algorithm for adults with Type 2 Diabetes. Topics include blood pressure targets, screening for secondary causes of hypertension, proper blood pressure measurement techniques, lifestyle interventions, and evidence based pharmacologic therapy. We discuss ACE inhibitors, ARBs, thiazide diuretics, calcium channel blockers, resistant hypertension management, mineralocorticoid receptor antagonists including spironolactone and finerenone, and the role of GLP-1 receptor agonists and SGLT2 inhibitors in blood pressure reduction. We also highlight board relevant treatment thresholds, cardiovascular risk reduction strategies, and key numbers to remember for exam preparation and clinical practice.